Abstract
111 children with heights below 2.5 SD fcr age (Tanner) were identified by screening of 7500 children, 6-14 years of age, in the Rehovot region. The total population of this age group is 40,000 in the area studied. The 111 children of short stature (ss) included: 8 skeletal disease, 2 Down Syndrome, 4 Thalassemia, 4 Turner, 3 celiac, 4 classical growth hormon deficiency (CGHD), 4 intrauterine growth retardation, 4 systemic disease, and 78 without obvious underlying disease. In 35 of the 78 subjects the 24 h. integrated concentration of growth hormone (ICGH) was in the hypopituitary range (< 3.2 ng/ml) and were thus diagnosed as having Neurosecretory Dysfunction (NSD). A one-year growth response to somatropin (recombinant GH, BioTropin, Bio-Technology General, Israel) of NSD patients, 19 of whom remained prepubertal throughout the study, was compared to CGHD patients. The response of both groups was similar, as summarized below: The frequency of NSD patients (45%) among ss without underlying pathology in the Rehovot region was consistent with that found in NSD diagnosed patients referred from other Israeli centers (35/78 and 99/221, respectively). The overall frequency of NSD in the population screened was 4/1000 children.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
